Liquidia Corporation

LQDA

$68.64

Updated: 23/09/2026, 01:11:21

Market Cap

$6.10B

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Country

Stock valuation chart

One-year closing share-price history for LQDA

Company Profile

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.

USD

NASDAQ

CEO: Roger A. Jeffs

Employees: 216

https://www.liquidia.com

Asset Summaries

Latest generated summaries for LQDA

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for LQDA.

Share price: $68.64
Market cap: $6.10B
Exchange: NASDAQ
Currency: USD
CEO: Roger A. Jeffs
Employees: 216
IPO date: 26/07/2018
Beta: 0.535
Last dividend: $0.00
Day range: $66.00 – $68.76
52-week range: $21.15 – $93.61
1-day performance: 3.33%
1-year performance: 224.54%
Current drawdown (1Y): -26.67%
CIK: 0001819576
CUSIP: 53635D202
ISIN: US53635D2027
Created: 07/12/2025, 05:06:23
Last update: 23/09/2026, 01:11:21

Track Liquidia Corporation with an AI analyst

See which prediction-market events move LQDA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to LQDA from your Railway `news_articles` table.

Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions

GlobeNewsWire • STOCK • 11/06/2026, 10:30:00

Liquidia Corp (LQDA) Stock Up 3.4% and Still Undervalued -- GF Score: 75/100

GuruFocus • STOCK • 08/06/2026, 21:24:00

Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index

GlobeNewsWire • STOCK • 08/06/2026, 10:30:00

4 Best Low-Beta Stocks to Buy Right Away: LQDA, CVX, OXY & VLO

Zacks Investment Research • STOCK • 05/06/2026, 14:15:26

Are You Looking for a Top Momentum Pick? Why Liquidia Corporation (LQDA) is a Great Choice

Zacks Investment Research • STOCK • 28/05/2026, 15:01:14

Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference

GlobeNewsWire • STOCK • 27/05/2026, 10:30:00

4 Low-Beta Stocks for a Steadier Portfolio: LQDA, XOM, VLO & FANG

Zacks Investment Research • STOCK • 20/05/2026, 14:46:10

Earnings Estimates Moving Higher for Liquidia Corporation (LQDA): Time to Buy?

Zacks Investment Research • STOCK • 14/05/2026, 15:21:09

Liquidia Corporation (LQDA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 13/05/2026, 16:00:51

Best Momentum Stocks to Buy for May 13th

Zacks Investment Research • STOCK • 13/05/2026, 13:02:21

Liquidia: Yutrepia's Launch Momentum Is Approaching A Ceiling (Rating Downgrade)

Seeking Alpha • STOCK • 12/05/2026, 07:18:38

Jefferies Boosts Price Target for Liquidia (NASDAQ: LQDA) on Strong YUTREPIA Performance

Market Data • Market Data • 11/05/2026, 23:25:44